Galectin Therapeutics (GALT) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Opus Genetics is the larger company by market cap ($366.9 million vs $365.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | GALT | IRD |
|---|---|---|
| Share price | $3.62 | $4.41 |
| Market cap | $365.08M | $366.89M |
| 1-day change | -3.72% | +0.68% |
| YTD return | -12.98% | — |
| 1-year return | -24.11% | — |
| 5-year return | +7.42% | — |
| EPS (TTM) | $-0.43 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.13 | $7.07 |
| 52-week low | $2.03 | $1.70 |
| Distance from 52-week high | -49.23% | -37.62% |
| Average volume | 387.94K | 2.35M |
| Shares outstanding | 100.85M | 83.20M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
GALT vs IRD FAQ
Which is bigger, Galectin Therapeutics or Opus Genetics?
Opus Genetics (IRD) is larger, with a market capitalization of $366.89M compared with $365.08M for Galectin Therapeutics (GALT).
Are Galectin Therapeutics and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.